Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Corporate Presentation is up

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Mar 05, 2021 4:00pm

95 Views

Post# 32730952

RE:RE:RE:RE:RE:RE:RE:New Corporate Presentation is up

How about a label expansion for Nash Hiv patients 18 mos into the trial after an interim review by DSMB ,,,,,

palinc2000 wrote: I have learned from SPCEO to read between the lines,So in reading between the lines I think they want the reader to conclude that the 75-100 Hiv patients cohort in the Nash trial has a good chance of success and that alone would represent a major market opportunity,,,,

I really enjoy reading their confidence level in getting substantial growth in sales of existing product

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security